Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 3Sarcoma 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Her-2 Negative Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Cancer Metastatic 1Advanced Solid Tumors 1

Interventions

Temozolomide 6Cyclophosphamide 5cabozantinib 4Vincristine 4fludarabine 3Radiotherapy 3Irinotecan 3liposomal doxorubicin 2irinotecan sucrosofate 2Zoledronic Acid 2Topotecan 2Specimen Handling 2PM 01183 2Ifosfamide 2Etoposide 2Eflornithine 2Drug Therapy 2Doxorubicin 2trilaciclib 1trifluridine tipiracil drug combination 1talazoparib 1silmitasertib 1romiplostim 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1naxitamab 1fluzoparib 1fludarabine phosphate 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Ewing × fluzoparib × Clear all
NCT06827717 2025-05-31

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

Sun Yat-sen University

Phase 2 Recruiting
29 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡